Physician profile
Debra Vance
NPI 1366922536
$1,492.40
in general payments reported to CMS, 2019-2025
22 companies · $1,002 in 2025
The $1,002 reported for 2025 was more than what 85% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $159 · 2022: $203 · 2023: $18.75 · 2024: $109 · 2025: $1,002.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,130.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $200.93 | 2024-2025 | Entyvio, Eohilia |
| Abbvie INC. | $182.96 | 2025 | |
| Phathom Pharmaceuticals, INC. | $132.92 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.74 | 2022 | |
| Ardelyx, INC. | $112.98 | 2024-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $88.87 | 2024-2025 | Dupixent |
| Madrigal Pharmaceuticals | $81.93 | 2025 | Rezdiffra |
| Janssen Pharmaceuticals, INC | $80.41 | 2021-2023 | Xarelto |
| Lilly USA, LLC | $66.13 | 2021-2025 | Omvoh |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.45 | 2025 | Xifaxan |
| Aimmune Therapeutics, INC. | $55.21 | 2025 | Vowst, Zenpep |
| Genzyme Corporation | $47.44 | 2025 | |
| Gilead Sciences, INC. | $43.16 | 2021 | |
| Janssen Biotech, INC. | $33.65 | 2025 | Tremfya |
| Organon LLC | $33.60 | 2025 | Renflexis, Hadlima |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $30.40 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $21.78 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.00 | 2021 | |
| Kci USA, INC. | $19.22 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $18.93 | 2021 | |
| Merck Sharp & Dohme LLC | $16.98 | 2021 | |
| Novo Nordisk INC | $14.71 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Vance listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.